A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib

被引：0
|
作者：
Jewitt, K.
Pilgrim, H. [1 ]
Ward, S. [1 ]
机构：
[1] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [31] Activity and Tolerability of Nilotinib A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant
    Koren-Michowitz, Maya
    le Coutre, Philipp
    Duyster, Justus
    Scheid, Christof
    Panayiotidis, Panayiotis
    Prejzner, Witold
    Rowe, Jacob M.
    Schwarz, Michaela
    Goldschmidt, Neta
    Nagler, Arnon
    CANCER, 2010, 116 (19) : 4564 - 4572
  • [32] Nilotinib leads to sustained responses in CML patients with residual disease on imatinib
    Fuerst, Mark L.
    FORMULARY, 2013, 48 (07) : 237 - 237
  • [33] Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
    Usala, Emilio
    CLINICAL MANAGEMENT ISSUES, 2011, 5 : 27 - 30
  • [34] Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib.
    Jabbour, Elias
    Kantarjian, Hagop
    Giles, Francis
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 616A - 616A
  • [35] Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib
    Choi, Soo Young
    Lee, Sung-Eun
    Oh, Yun Jeong
    Kim, Soo-Hyun
    Woodman, Richard C.
    Szczudlo, Tomasz
    Jootar, Saengsuree
    Kim, Hyeoung-Joon
    Sohn, Sang Kyun
    Park, Joon Seong
    Kim, Sung-Hyun
    Zang, Dae-Young
    Oh, Suk-Joong
    Kim, Dong-Wook
    BLOOD, 2014, 124 (21)
  • [36] EFFICACY OF NILOTINIB VS HIGH-DOSE IMATINIB VS SUSTAINING STANDARD-DOSE IMATINIB IN EARLY CHRONIC PHASE CML PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSE TO FRONTLINE IMATINIB
    Choi, S. Y.
    Lee, S. E.
    Kim, S. H.
    Woodman, R.
    Szczudlo, T.
    Jootar, S.
    Kim, H. J.
    Sohn, S. K.
    Park, J. S.
    Kim, S. H.
    Zang, D. Y.
    Oh, S. J.
    Kim, D. W.
    HAEMATOLOGICA, 2015, 100 : 439 - 439
  • [37] COST-UTILITY ANALYSIS OF BOSUTINIB FOR PREVIOUSLY TREATED CHRONIC MYELOID LEUKEMIA (CML) IN PORTUGAL
    Paquete, A. T.
    Ines, M.
    Duarte, I
    Almeida, A.
    Esteves, S.
    Miguel, L. S.
    VALUE IN HEALTH, 2014, 17 (07) : A533 - A533
  • [38] Management of imatinib-resistant CML patients
    Linke, Rolf
    Dempke, Wolfram
    ONKOLOGIE, 2007, 30 (11): : 574 - 580
  • [39] COST-UTILITY ANALYSIS IN UROLOGY
    Fero, Katherine
    Sharma, Vidit
    Lec, Patrick
    Saigal, Christopher
    Chamie, Karim
    JOURNAL OF UROLOGY, 2021, 206 : E435 - E436
  • [40] Cost-utility analysis for UTIs
    Schaefer, SE
    JOURNAL OF FAMILY PRACTICE, 1997, 44 (04): : 329 - 329
12345